Sign up
Pharma Capital
Market: AIM
52-week High/Low: 175.00p / 40.00p
Sector: Pharma & Biotech
Market Cap: 42.22M

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by...

Silence Therapeutics PLC

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Silence Therapeutics PLC

Silence Therapeutics PLC Snapshot



Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value.

Silence’s strategy is based on translating our intellectual property, our siRNA technology and delivery systems, into successful commercial drug products. We have the expertise and the patented technology required to develop siRNA based drug candidates internally as well as to establish fruitful collaborations with suitable partners.

Ensuring appropriate target gene selection and maintaining a diversified pre-clinical engine are key aspects of our strategic approach. We aim to evaluate as many potential applications of our technology as possible in the early, more affordable phases of our candidate-generating pipeline in order to better manage risk and the costs of failure.

Our strategy plays to the strengths of our platform technology, which include:


Our siRNA molecules are designed to target a single mRNA in the cell, only affecting the expression of the disease-causing gene. Our delivery systems ensure further specificity by delivering therapeutic siRNA only to one target cells in the body.

Modular technology

Our technology consists of two components: siRNA plus delivery system.

By engineering the siRNA molecule, a different gene can be targeted to tackle a new disease. This modular nature is the basis of our versatile platform technology.

Well understood mode of action

RNA interference is a well characterised natural pathway, which leads to the degradation of target mRNA. The precision of the RNA interference process translates in better predictability of the biological effects of siRNA based drugs.

Accelerated discovery timelines

Knowing the sequence of the human genome means that potent therapeutic siRNA molecules can be identified quickly, ready to be tested in the relevant models.

BusinessModel_144dpi.png (1)


Click here to view our Pipeline

Click here to view Our Technology



Management Team

Our management team is highly experienced in a variety of relevant sectors, from molecular biology and genetics to pharmaceutical development, BD deals and corporate finance. This combination of skill sets enables the team to effectively execute our business plan.


Chief Executive Officer
Dr. David Horn Solomon

Chief Financial Officer
David Ellam

* including indirect holdings and financial instrumentsNumber of securities in issue: 69,991,624 ordinary sharesPercentage of AIM securities not in public hands: 63.71% as at 30th September 2017.Last updated: 30th September 2017

Email - [email protected]

Corporate Headquarters - UK 
72 Hammersmith Road,
W14 8TH
t +44 (0)20 3457 6900

Robert-Rössle-Str. 10
D-13125 Berlin

t +49 30 9489 2800

Key advisers

Nominated adviser and joint broker

Peel Hunt LLP
Moor House
120 London Wall
+44 (0) 20 7418 8900

Legal adviser

Covington & Burling LLP
265 Strand
+44 (0) 20 7076 2000


PricewaterhouseCoopers LLP
Abacus House
Castle Park
+44 (0) 1223 460055


Link Asset Services
65 Gresham Street
+44 (0)870 402 7570

European Media & Investor Relations

Consilium Strategic Communications
41 Lothbury
+44 (0) 20 3709 5700

US Investor Relations

Burns McClellan
257 Park Avenue South
15th Flr.
New York
+1 (212) 213 0006


View full SLN profile View Profile
View All

Market Reports Including SLN


Executive video interviews


© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.